Glatiramer Acetate or glatiramer (GA; trademark Copaxone® by Teva Pharmaceutical Industries, Ltd.) is licensed in much of the world for relapsing-remitting multiple sclerosis (MS). In early trials of the drug, it was known as Copolymer-1 and Cop-1.

Glatiramer reduces the average relapse rate in people with the relapsing-remitting (RRMS) form MS. The formation of new MS-related lesions in the central nervous system and rate of brain atrophy are also reduced.

Licensing